Amphotericin B (AmB) is still the most common antifungal medication in the treatment of systemic fungal infections. Generally, AmB is restricted to intravenous administration in the medical application, accompanied by dose-dependent severe nephrotoxicity, hepatotoxicity, allergic shock, and so on. To date, various drug delivery vehicles have been designed to develop the oral formulation of AmB. Importantly, AmB-loaded nanocochleate is an interesting formulation that has entered clinical trial, showing a favorable clinical outcome upon oral administration. Thus, this review summarizes the recent advances in the oral preclinical and clinical trials of AmB-loaded nanocochleates.